Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes

Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes

Abstract Insulin-like growth factor 1 (IGF-1) is a determinant of bone mass and is inversely associated with vertebral fractures (VFs). Sclerostin regulates bone formation by inhibiting Wnt/β-catenin signaling. Currently, there is little information on circulating sclerostin levels among postmenopau...

Full description

Saved in:
Bibliographic Details
Published in:Bone (New York, N.Y.) Vol. 56; no. 2; pp. 355 - 362
Main Authors: Ardawi, Mohammed-Salleh M, Akhbar, Daad H, AlShaikh, Abdulrahman, Ahmed, Maimoona M, Qari, Mohammed H, Rouzi, Abdulrahim A, Ali, Ahmed Y, Abdulrafee, Adel A, Saeda, Mamdouh Y
Format: Journal Article
Language:English
Published: Amsterdam Elsevier Inc 01-10-2013
Elsevier
Subjects:
Aged
Biological and medical sciences
Bone Density - physiology
Bone Morphogenetic Proteins - blood
Bone turnover markers
Diabetes
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - physiopathology
Diabetes. Impaired glucose tolerance
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Female
Fundamental and applied biological sciences. Psychology
Genetic Markers
Humans
IGF-1
Injuries of the limb. Injuries of the spine
Insulin-Like Growth Factor I - metabolism
Medical sciences
Middle Aged
Orthopedics
Postmenopausal women
Postmenopause
Sclerostin
Spinal Fractures - blood
Traumas. Diseases due to physical agents
Vertebrates: anatomy and physiology, studies on body, several organs or systems
Sclerostin
IGF-1
Postmenopausal women
Diabetes
Bone turnover markers
Endocrinopathy
Human
Type 2 diabetes
Diseases of the osteoarticular system
Metabolic diseases
Vertebra
Fracture
Bone remodeling
Insulin like growth factor 1
Trauma
Morphology
Postmenopause
Serum
Woman
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Insulin-like growth factor 1 (IGF-1) is a determinant of bone mass and is inversely associated with vertebral fractures (VFs). Sclerostin regulates bone formation by inhibiting Wnt/β-catenin signaling. Currently, there is little information on circulating sclerostin levels among postmenopausal women with type-2 diabetes mellitus (T2DM) with VFs in relation to serum IGF-1 (s-IGF-1). We investigated the relationships between serum sclerostin, s-IGF-1, and VFs in postmenopausal women with T2DM. We assessed cross-sectionally 482 postmenopausal women with T2DM and 482 age-matched postmenopausal women without T2DM who were recruited at diabetic clinics and primary health care centers for inclusion in a bone health survey. The main outcome measures were serum sclerostin, s-IGF-1, bone mineral density (BMD), and bone turnover markers. Lateral X-rays of the thoracic and lumbar spine were taken to diagnose VFs. Serum sclerostin levels were increased, whereas s-IGF-1 levels were decreased when T2DM women were stratified by the number of VFs (P < 0.0001). Multiple logistic regression analysis showed that serum sclerostin levels were positively associated with 1 VF (odds ratio [OR] = 1.27, (95%CI:1.01–2.03), P = 0.016), 2 VFs (OR = 1.41, (95%CI:1.03–2.36), P = 0.006), and ≥ 3 VFs (OR = 1.54, (95%CI:1.12–2.44) P = 0.005). s-IGF-1 levels were inversely associated with 1 VF (OR = 0.58, (95%CI:0.39–0.88), P = 0.041), 2 VFs (OR = 0.42, (95%CI:0.21–0.90), P = 0.012), and ≥ 3 VFs (OR = 0.19, (95%CI: 0.14–0.27), P < 0.001). Increased serum sclerostin and decreased s-IGF-1 were associated with VFs among postmenopausal women with T2DM, suggesting that sclerostin and/or IGF-1 may be involved in increased bone fragility in T2DM and could be potential markers of VF severity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:8756-3282
1873-2763
DOI:10.1016/j.bone.2013.06.029